DDInter463 DDInter255
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Dacarbazine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Dacarbazine {u} (Compound) upregulates {v} (Gene) CADM1
CADM1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Dacarbazine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Busulfan
Dacarbazine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Busulfan
Dacarbazine {u} (Compound) upregulates {v} (Gene) CADM1
CADM1 {u} (Gene) is regulated by {v} (Gene) PSMD2
PSMD2 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Dacarbazine {u} (Compound) treats {v} (Disease) skin cancer
skin cancer {u} (Disease) is associated with {v} (Gene) CDK4
CDK4 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Dacarbazine {u} (Compound) treats {v} (Disease) skin cancer
skin cancer {u} (Disease) is associated with {v} (Gene) TERT
TERT {u} (Gene) is upregulated by {v} (Compound) Busulfan
Dacarbazine {u} (Compound) upregulates {v} (Gene) CADM1
CADM1 {u} (Gene) is regulated by {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Dacarbazine {u} (Compound) treats {v} (Disease) pancreatic cancer
pancreatic cancer {u} (Disease) downregulates {v} (Gene) SLC25A4
SLC25A4 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Dacarbazine {u} (Compound) treats {v} (Disease) pancreatic cancer
pancreatic cancer {u} (Disease) downregulates {v} (Gene) C5
C5 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Dacarbazine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Dacarbazine (Compound) upregulates CADM1 (Gene) and CADM1 (Gene) is upregulated by Busulfan (Compound)
Dacarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Busulfan (Compound)
Dacarbazine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with GSTM1 (Gene) and GSTM1 (Gene) is bound by Busulfan (Compound)
Dacarbazine (Compound) upregulates CADM1 (Gene) and CADM1 (Gene) is regulated by PSMD2 (Gene) and PSMD2 (Gene) is upregulated by Busulfan (Compound)
Dacarbazine (Compound) treats skin cancer (Disease) and skin cancer (Disease) is associated with CDK4 (Gene) and CDK4 (Gene) is downregulated by Busulfan (Compound)
Dacarbazine (Compound) treats skin cancer (Disease) and skin cancer (Disease) is associated with TERT (Gene) and TERT (Gene) is upregulated by Busulfan (Compound)
Dacarbazine (Compound) upregulates CADM1 (Gene) and CADM1 (Gene) is regulated by MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Busulfan (Compound)
Dacarbazine (Compound) treats pancreatic cancer (Disease) and pancreatic cancer (Disease) downregulates SLC25A4 (Gene) and SLC25A4 (Gene) is downregulated by Busulfan (Compound)
Dacarbazine (Compound) treats pancreatic cancer (Disease) and pancreatic cancer (Disease) downregulates C5 (Gene) and C5 (Gene) is upregulated by Busulfan (Compound)